Acquired Resistance to Therapy Network (ARTNet)

Acquired Resistance to Therapy Network (ARTNet)

@nciartnet.org

Official Account of the National Cancer Institute Acquired Resistance to Therapy Network (ARTNet). https://www.nciartnet.org/

116 followers39 following153 posts

Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

At today's #ARTNetSCMeeting, Dr. Alan Hutson provided network updates, followed by a presentation from Dr. Vlad Sandulache of Baylor College of Medicine on modeling tumor–tumor immune microenvironment (TIME) interactions across time and space in head and neck squamous cell carcinoma (HNSCC).

Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

New research identifies TNIK as a potential driver of chemoradiation resistance in limited-stage small cell lung cancer (SCLC). 🔗 pubmed.ncbi.nlm.nih.gov/41838988/ #ARTNetPublication #SCLC #LungCancer #CancerResearch #RadiationOncology #PrecisionOncology

pubmed.ncbi.nlm.nih.govTNIK Overexpression Is Sufficient for Chemoradiation Resistance in Limited-Stage Small Cell Lung Cancer - PubMedSmall cell lung cancer (SCLC) is characterized by early metastasis, intrinsic chemoradiation resistance, and tumor recurrence. Besides the lack of potentially targetable oncogenic drivers, therapeutic advancements are also hindered by the scarcity of surgically resected tissue specimens ideal for pr …

Acquired Resistance to Therapy Network (ARTNet) reposted

Cancer Cell
@cp-cancercell.bsky.social

Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy

dlvr.itSubclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapyMallard de La Varende et al. demonstrate that gut dysbiosis impairs tumor immunosurveillance through the gut-liver axis, causing subclinical cholestasis and immunotherapy resistance in tumors distant from gastrointestinal and hepatic tissues. Gut dysbiosis triggers plasma elevation of γ-glutamyl transferase, increase in TCDCA in humans (TMCA in mice), and drop in sMAdCAM-1 levels.
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

A fascinating episode and well worth your time! #ARTNetPodcast Episode 2: theartnetpodcast.riverside.com/e/resistance...

theartnetpodcast.riverside.comResistance Before Treatment Begins: Why Some Tumors Are Already Primed to SurviveWhy do some cancers fail treatment from the very beginning? In this episode of the ARTNet Podcast, Dr. David Goodrich speaks with Dr. Vlad C. Sandulache of Baylor College of Medicine about emerging re...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

📢 Registration is now open for the NCI Workshop on Understanding Plasticity and its Role Across the Cancer Continuum! 🗓️ September 23–24, 2026 💻 In-person speakers & virtual public participation Register here: events.cancer.gov/dcb/plastici...

events.cancer.govWorkshop on Understanding Plasticity and its Role Across the Cancer Continuum (Overview) | Events RegistrationOverviewSignificant challenges exist in understanding and tackling tumor heterogeneity across the initiation-progression-resistance spectrum. Central to this challenge is cellular plasticity, which co...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

How do cancer-driving fusion proteins create their own vulnerabilities?A #ARTNetPublication in Cancer Research co-authored by Dr. Trever Bivona shows FET fusion oncoproteins impair ATM-mediated DNA damage repair, forcing tumors to rely on ATR signaling for survival. pubmed.ncbi.nlm.nih.gov/41811428/

pubmed.ncbi.nlm.nih.govFET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy - PubMedFET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields-oncogene biology and DNA repair-and proposing ATR inhibition as a targeted therapeutic approach fo...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

How do cancer-driving fusion proteins create their own vulnerabilities?A new #ARTNetPublication co-authored by Dr. Trever Bivona shows that FET fusion oncoproteins impair ATM-mediated DNA damage repair, forcing tumors to rely on ATR signaling for survival. pubmed.ncbi.nlm.nih.gov/41811428/

pubmed.ncbi.nlm.nih.govFET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy - PubMedFET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields-oncogene biology and DNA repair-and proposing ATR inhibition as a targeted therapeutic approach fo...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

🎙️ The inaugural episode of the #ARTNetPodcast is now live theartnetpodcast.riverside.com Join Dr. David Goodrich of @roswellpark.bsky.social & Dr. Jeff Tyner of @ohsuknight.bsky.social as they discuss cancer resistance, tumor evolution, & ARTNet’s mission to advance collaborative resistance research

theartnetpodcast.riverside.comThe ARTNet Podcast<p>Why do cancer treatments work for some patients at first, only to stop working later? In the premiere episode of the <a rel="noopener noreferrer nofollow" href="https://www.nciartnet.org?utm_source...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

At today’s Functional Screens and Assays #ARTNetWGMeeting, Dr. Anton Windfelder from the Fraunhofer Institute for Molecular Biology shared fascinating research on host-pathogen interactions using caterpillars as a model organism. The presentation sparked a highly engaging discussion .

Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

New review just out: Drs. Erik S. Knudsen, Agnieszka K. Witkiewicz, and Sheheryar Kabraji of @roswellpark.bsky.social outline the evolving landscape of CDK inhibition: from the success of CDK4/6 inhibitors in breast cancer to next-gen strategies expanding into other tumor types. #CDK #BreastCancer

Nature Reviews Drug Discovery@natrevdrugdiscov.nature.com

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond www.nature.com/articles/s41... rdcu.be/ffR0W This new Review discusses how combination strategies, novel CDK2- and CDK4-selective inhibitors and biomarkers are addressing drug resistance and expanding therapeutic uses

nature.comThe evolving landscape of CDK inhibitor use in breast cancer therapy and beyond - Nature Reviews Drug DiscoveryTen years after the first FDA approval, CDK inhibition is entering a new phase in oncology. This Review examines how combination strategies, emerging CDK2- and CDK4-selective inhibitors, and developin...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

New funding opportunity 🚨 National Cancer Institute (NCI) Division of Cancer Biology (DCB) has published FY26 Topics of Interest for Administrative Supplements. Check details here: www.cancer.gov/about-nci/or...

cancer.govDCB Topics of Interest for Administrative Supplements in FY26NIH policy allows for administrative supplements within the scope of the peer-reviewed and approved project to support costs and activities unforeseen at the time of the parent grant award. We provide...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

At today’s #ARTNetSCMeeting, Dr. Alan Hutson shared network updates and warmly welcomed new associate member Dr. Jennifer Wargo. Dr. Yu-Ting Chou presented on “Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in #NSCLC.”

Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

New #ARTNetPublication: A study by Dr. Trever Bivona and colleagues reveals that the pan-RAF inhibitor exarafenib shows strong activity against BRAF Class II/III NSCLC, a population with no approved targeted therapies and representing ~65% of BRAF-mutant cases. Read more: doi.org/10.1038/s414...

doi.orgPan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies - Nature CommunicationsWhile therapies targeting type I BRAF mutations have been developed, there are limited options for those with type II and III mutations. Here, the authors identify a subset of BRAF-mutant non-small ce...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

New #ARTNetPublication introduces MultiMap, a temporal photoproximity labeling approach to track dynamic EGFR interaction neighborhoods in real time. pubmed.ncbi.nlm.nih.gov/41254216/

pubmed.ncbi.nlm.nih.govTemporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap - PubMedPhotoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both out …
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

Congrats to all the authors! #ARTNetPublication

Soragni:Lab@alice.soragnilab.com

Proud of this review on centering models and next gen techs to address and prevent acquired resistance in cancer. Cements the work that our working group within @nciartnet.org has done over the last couple years, glad it resonated with people

Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

At today’s #ARTNetSCMeeting, Dr. Alan Hutson provided network updates. Drs. Shannon McWeeney and Daniel Bottomly highlighted a newly published study in Scientific Data, a collaborative effort across the ARTNet Consortium. Read the paper: www.nature.com/articles/s41...

nature.comBiomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML - Scientific DataScientific Data - Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

At today's Cell State, Metabolism & Inflammatory Microenvironment #ARTNetWGMeeting, Dr. Nina Grace Steele of University of Cincinnati presented on extracting mechanisms of cellular talk in pancreatic acancer using big data,sparking a lively and engaging discussion.

Acquired Resistance to Therapy Network (ARTNet) reposted

CAP-IT
@ncicapit.org

Save the date! The #CAPITSummit is happening on March 30, 2026. A full day of science, strategy, and community—bringing together researchers, clinicians, and advocates to advance cancer prevention and interception. Register now and join us: tinyurl.com/5c6snwyz

tinyurl.comRegistration for the NCI CAP-IT Annual Summit: March 30, 2026The upcoming NCI CAP-IT Summit is set to convene a diverse mix of participants, including senior leaders, experts, and emerging talents such as junior investigators and trainees, all dedicated to the ...
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

New #ARTNetPublication: Using paired photoproximity labeling (PLP) workflows, researchers dynamically mapped EGFR signaling neighborhoods inside and outside cells, capturing interactome changes within minutes to hours after EGF stimulation. pubmed.ncbi.nlm.nih.gov/41254216/

pubmed.ncbi.nlm.nih.govTemporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap - PubMedPhotoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both out …
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

Lineage plasticity fuels drug resistance in prostate cancer but it may be reversible. This study in Nature shows targeting the histone methyltransferase NSD2 reverses plasticity in castration-resistant prostate cancer. pubmed.ncbi.nlm.nih.gov/41299174/

pubmed.ncbi.nlm.nih.govNSD2 targeting reverses plasticity and drug resistance in prostate cancer - PubMedLineage plasticity is a cancer hallmark that drives disease progression and treatment resistance<sup>1,2</sup>. Plasticity is often mediated by epigenetic mechanisms that may be reversible; however, there are few examples of such reversibility. In castration-resistant prostate cancer (CRPC), plastic …
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

Drug-resistant NSCLC cells harbor an unexpected vulnerability: heightened mechanosensitivity. Read this #ARTNetPublication by Dr. Trever Bivona, from the ARTNet BAATAAR-UP U54 at UCSF. pubmed.ncbi.nlm.nih.gov/41443038/

pubmed.ncbi.nlm.nih.govDrug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerability - PubMedDrug resistance is a leading cause of cancer treatment failure and tumor recurrence. Identifying new methods that eliminate life-threatening drug-resistant cancer cells (DRCs) can enhance tumor cell eradication and improve patient outcomes. Here we report that human non-small cell lung cancer (NSCLC …
Acquired Resistance to Therapy Network (ARTNet)
@nciartnet.org

Join SITC and NCI for the Computational Immuno-oncology Webinar Series Course 9: Using Spatial Biology to Monitor Tumor Immune Interactions on Nov. 13, 2025 (1–2 p.m. ET). Register for this free digital event: sitcancer.org/CompIO

sitcancer.org2025 SITC-NCI Computational Immuno-Oncology Webinar Series | Ten Free WebinarsIn partnership with the National Cancer Institute (NCI), SITC is pleased to launch a new series of ten computational immuno-oncology webinars that will focus specifically on advanced methods and clini...